The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2019 | ALK-TKIs: targeted therapies for ALK-positive NSCLC
Antonio Passaro, MD, PhD, of European Institute of Oncology IRCCS, Milan, Italy, discusses the changing treatment landscape for ALK-positive non-small cell lung cancer (NSCLC). Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Dr Passaro reports that whereas chemotherapy was the major treatment option in the past, newly emerging targeted therapies prompted the introduction of ALK tyrosine kinase inhibitors (TKIs) as the first-line treatment for ALK-positive NSCLC.
